Objective The aim of this study was to evaluate the efficacy, reasons for switching and drug survival of TNF-a inhibitors (TNFis) used as first-and second-line drugs in ankylosing spondylitis (AS). Methods Data on patients suffering from AS and treated with at least one TNFi between November 2005 and 2013 were extracted retrospectively from the database of a single clinical centre. Beside demographic data, the disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the response rates (BASDAI50), reasons for switching and survival curves of TNFis were analysed in general and in subgroups of patients treated with each of the available TNFis. The reasons for switching were defined as inefficacy, side effects of the given drug, patient's request and occurrence of extra-articular manifestations. Results Altogether, 175 patients were on TNFis and 77 of them received at least two TNFis. The patients' age at the initiation of the first TNFi was higher among switchers compared to non-switchers (42.5 ± 12.6 vs. 38.8 ± 11.2 years, p = 0.049); otherwise, gender, disease duration and initial disease activity had no influence on the risk of switching. The decrease of the BASDAI was similar among non-switchers and switchers using either the first or second TNFi, but the response rates to the first and second TNFi were worse in switchers than in non-switchers.
Introduction
During the last decade, TNF-a inhibitors (TNFi-s) have revolutionised the treatment of ankylosing spondylitis (AS) patients who failed to respond to non-steroidal antiinflammatory drugs (NSAIDs) and physical therapy. According to the meta-analysis of randomised controlled trials (RCTs), it became evident that all available TNFis (adalimumab, etanercept, infliximab and golimumab) exert similar effects on the signs and symptoms of the axial components of the disease [1] [2] [3] [4] [5] .
The use of TNFis in patients with AS is regulated by the Assessment in Spondyloarthritis International Society (ASAS) recommendations, which usually serve as a basis for national protocols. On the basis of the ASAS guideline, AS patients eligible for TNFi therapy are those who have active disease as determined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and do not respond to at least two NSAIDs [6] . Although the ASAS/European League Against Rheumatism (EULAR) recommendation clearly states that there are no differences in efficacy among the TNFis on the axial and articular/entheseal disease manifestations [7] , it has been documented in several clinical trials that the anti-TNF monoclonal antibodies (adalimumab, infliximab and golimumab) can be used successfully in the treatment of most common extra-articular manifestations of the disease, while etanercept has milder effect on uveitis and inflammatory bowel diseases [8, 9] . According to these observations, the difference in gastrointestinal efficacy of each TNFi is suggested to be taken into account by ASAS/ EULAR guidelines [7] , but beyond this aspect, there are no therapeutic recommendations on how to choose between TNFis or how to switch between these agents.
Biological therapy provides significant improvement in disease activity, functional capacity and disease-related quality of life for most AS patients over a long term period, even after an 8-year-long continuous treatment [10] . However, some of the patients may not respond properly to the initial TNFi and their symptoms worsen over time. Another proportion of patients experience side effects related to the drug which interfere with the continuation of the treatment. As the TNFis are structurally different and they have different mechanisms of action, an unsuccessful treatment with one drug does not preclude response to another [11] .
The efficacy of switching between TNFis in AS and axial spondyloarthritis (SpA) has been evaluated in a limited number of large studies. In the RAPID-axSpA trial, \40 % of patients could be successfully treated with a TNFi for a period more than 3 months before certolizumab pegol treatment, if the reason for discontinuation was other than primary failure. The subgroup analysis of the trial has not yet been published [12] . In an open-label trial, 26.1 % of 1,250 AS patients treated with adalimumab had previously received etanercept and/or infliximab. Among patients who used adalimumab as a second-line treatment, worse response rates of the BASDAI50, ASAS40 and partial remission could be observed compared to patients treated with this drug as a first-line choice [13] .
The Danish and Norwegian national registries provide data on AS patients who switched to another biologic [14, 15] . In the DANBIO registry, data on 432 patients who switched to a second and those of 137 patients who switched to a third TNFi were analysed and compared to the data of 1,004 non-switchers. It was concluded that response rates and drug survival were lower among switchers. The NOR-DMARD register evaluated the effectiveness of second TNFis among 77 switchers with AS, and switching to a second TNFi was found to be useful in daily practice, although it results in lower overall effectiveness.
As available data on the efficacy of primary and subsequent TNFi therapy and predictive factors of the effectiveness of the second choice drug are controversial, and few systematic analyses of the reasons for switching and the treatment responses of each TNFi among switchers and non-switchers have been published, we wished to assess these issues under real-world circumstances. In the present study, the reasons for switches, the effect of TNFis on disease activity among switchers and non-switchers, and the predictive factors of effectiveness and drug survival were analysed in a relatively large number of AS patients treated in a single rheumatology centre.
Patients and methods
All AS patients treated with any TNFis at the Department of Rheumatology, University of Debrecen, Hungary between November 1, 2005 and November 30, 2013 were included in this study. A total of 175 AS patients, as defined by the modified New York criteria, were included in the study. Ninety-eight patients remained on the first-line TNFi, while 77 of them were treated with at least two different biologics. First and subsequent therapies were one of the following four drugs: adalimumab, etanercept, golimumab and infliximab. These biologics were used according to the standard clinical practice: adalimumab 40 mg every second week subcutaneously (sc); etanercept 50 mg weekly sc; golimumab 50 mg monthly sc; and infliximab 5 mg/kg every eight weeks intravenously (iv) after induction doses at baseline, and after 2 and 6 weeks. All biologics were administered according to the Hungarian national protocol, which is similar to the ASAS recommendations [6, 16] . Before TNFi therapy, all patients had active disease defined by elevated BASDAI (C4 on a visual analog scale, 0-10) despite prior treatment with at least two different NSAIDs or at least one NSAID if it was not tolerated or without prior NSAID treatment if it was contraindicated.
The reasons for switches between TNFis were inadequate response to the drug as defined by elevation of the BASDAI at two subsequent controls to 4 or above at 3 months after the initiation. The other reasons for stopping therapy and/or switches were side effects or patient's request (e.g. request to change from iv to sc administration or planned pregnancy) or development of a new extraarticular manifestation. The reasons for switching were classified into prespecified categories: primary and secondary inefficacy (IE), side effects of the drug (SE), appearance of extra-articular manifestation requiring switching (EA) and patient's request. There were three patients who were treated further in another rheumatology centre and it was impossible to obtain accurate information about their disease, so they were excluded from further data analysis. S94 K. Gulyas et al.
The study design was a retrospective, single-centre, observational analysis with assessments performed at baseline, and after 3, 6 and 12 months. The demographics of the patients, date of diagnosis, start and stop date of each biologic therapy, the BASDAI at baseline and during treatment, response rates (BASDAI50) and reasons for switches were collected.
We used the product limit method of Kaplan and Meier to estimate how long a patient remained on a given biological drug. Drug survival was calculated as the number of months between the dates of the first and last doses of the same drug. As adalimumab and especially golimumab were approved later for the treatment of AS than infliximab and etanercept, the follow-up periods were shorter in the case of the aforementioned drugs.
Data were analysed using the IBM SPSS 20 statistical software. Baseline demographics and disease characteristics were analysed with frequency calculation and descriptive statistics (Chi-square test, independent samples t-test and the Mann-Whitney test). The estimated drug survivals were calculated by the Kaplan-Meier method. We used the log-rank test to compare the distributions. p \ 0.05 was considered significant.
Results

General characteristics
Of the 175 AS patients who were treated with any of the TNFis, 77 switched to a second and 11 out of 77 to a third TNFi. Infliximab was the most commonly administered TNFi as a first-choice treatment. Out of 68 patients treated with this drug, 39 patients (57 %) required switch to a second TNFi. These ratios were 10 out of 40 (25 %) with adalimumab, 25 out of 58 (43 %) with etanercept and 3 out of 9 (33 %) with golimumab, respectively. As a thirdchoice treatment, golimumab was used most often (6 patients), followed by adalimumab and etanercept (3 and 2 patients, respectively) (Fig. 1) .
The baseline characteristics for patients treated with and without switching of TNFis are summarised in Table 1 . Significant differences were found between the two groups with regards to the age of patients at the initiation of the first TNFi. Patients who switched TNFi during the course of their disease were older compared to non-switchers (42.5 ± 12.6 years vs. 38.8 ± 11.2 years; p = 0.049).
Non-switchers Switchers Effectiveness of treatment
The effect of treatment assessed by the BASDAI was followed during the first 12 months. The improvement of the BASDAI to the first-choice drug was similarly significant among switchers and non-switchers (at the start of treatment: 7.06 ± 1.30 and 7.11 ± 1.18; p = 0.468, at month 3: 2.38 ± 1.21 and 3.15 ± 1.98; p = 0.058 among nonswitchers and switchers, respectively). Although a worsening of the BASDAI could be seen among switchers who used golimumab between the 6th and 12th months, it can be explained by the increase of this value for a single patient. As the number of patients on golimumab was rather small compared to other treatment groups, this result is difficult to interpret. The data of patients who underwent two switches were not analysed because of the low number of patients belonging to each treatment group. Analysing the BASDAI values after switching all of the second TNFis led to similar improvements between 0 and 3 months as could be observed by using the first TNFi (5.44 ± 2.40 and 2.16 ± 1.58, respectively), although the initial BASDAI values before switching were lower than in TNFi-naïve patients, since a significant proportion of them switched due to side effects of the first drug and it was associated with low BASDAI values before starting the second TNFi. However, after this period a worsening of the BASDAI could be detected between the 6th and 12th months in eight patients treated with infliximab (Fig. 2) . The response rates to the first TNFi measured by the BASDAI50 were generally inferior among the 77 switchers than among the 98 non-switchers (at the 3rd, 6th and 12th months 72.3, 74.6 and 70.8 % in nonswitchers and 56.0, 51.0 and 54.3 % in switchers, respectively). The treatment with the second TNFi after 3, 6 and 12 months achieved similar BASDAI50 responses (51.6, 50.9 and 46.9 %, respectively) to those of switchers to the first TNFi.
Reasons for switching
The reason for switching to a second TNFi was IE in most cases (42 patients out of 77). Switching was necessary due to any type of adverse events (AEs) in 23 patients. These AEs most often included infusion reactions in patients treated with infliximab and localised/generalised reactions to sc injections. The patient's request was the cause of switching in five cases, which resulted in four switches in the infliximab and one in the adalimumab group. During TNFi therapy, six extra-articular manifestations (three uveitis flares, two inflammatory bowel diseases and one psoriasis) developed that required switching. Most of these patients were treated with etanercept and, after the occurrence of these manifestations, they were switched to any of the anti-TNF monoclonal antibodies, which can be used more effectively in these comorbidities. While the most common reason for switching was IE in the adalimumab, etanercept and golimumab groups, the ratios of IE and SE necessitating the stopping of use of the first-choice drug were almost equal among infliximab-treated patients (Table 2) .
Drug survival
In our study, the overall survival times of first- Fig. 3 , there is an impression that remaining on first-line therapy was superior among patients treated with adalimumab and etanercept compared with infliximab users. Among patients who used infliximab as the first-line drug, a sharp decrease could be observed in drug survival between the 13th and 17th months of treatment (at month 13: 84.5 %, at month 17: 71.0 %). Due to the abovementioned reason, the retention curve of golimumab is shorter than those of other drugs. Although the number of Real-life experience with switching TNF-a S97 treated patients in each group is rather low after switching, the best drug adherence could be experienced in golimumab and the worst in the infliximab-treated patients.
Discussion
According to our single-centre observational study, almost half of the AS patients treated with TNFi switch their initially used drug to another, while only a small proportion of them would switch to a third TNFi during a follow-up period of up to 8 years. Switches could be detected more frequently among older patients. Although the efficacy of first and second TNFis seemed to be similar, as no differences could be measured between each TNFis by the decrease of the BASDAI values, the retention rate of infliximab was worse than those of other TNFis. The most common reasons for switching were the loss of effect among adalimumab-, etanercept-and golimumab-treated patients, while in infliximab-treated patients, the ratio of IE and side effects led to switching were almost equal. The effectiveness and safety of biological drugs in AS have been proved by RCTs. Cost-effectiveness models with input from RCTs, however, represent results obtained under rigorous experimental conditions. The precision and applicability of these data to other settings may be argued. In the real world of prescription and use, drugs are applied in a broader population and the use of concomitant medicines may vary, the same as patients' compliance and their expectations for health [17] . Moreover, biological drug sequences that do indeed occur in everyday practice (e.g. switch to a third or fourth drug, and then return to a previous one) have never been studied in RCTs. These discrepancies may alter both effectiveness and safety, as well as drug survival rates. Thus, alongside the growing body of actual practice data with biologicals, there is an increasing need to use registry data in cost-effectiveness analyses that reinforces their value. Moreover, the demand for health technology assessments (HTAs) based on local data is getting greater and greater [18] [19] [20] [21] [22] .
National registries and observational studies have proven that the frequencies of switches between biologics are higher among patients with rheumatoid arthritis and psoriatic arthritis than in AS, even though patients with peripheral arthritis are usually treated with disease-modifying antirheumatic drugs (DMARDs), which, at least theoretically, should postpone the loss of effect. The ratios of AS patients who switched to a second TNFi out of TNFi-treated patients were 15 and 30 % in Norwegian and Danish nationwide registries, respectively, in 8-9 years of follow-up. Similar switching frequencies (13-15 %) have been published in observational studies which included around 100 AS patients [23, 24] . In contrast, in our retrospective study, a much higher frequency of switching could be detected. It can be explained by the strict Hungarian regulation of the monitoring of effectiveness during the course of treatment. According to this regulation, the TNFi is considered to be effective if the BASDAI value decrease at least 50 % or 2 units between baseline and the third month of treatment and the BASDAI values do not exceed the value observed at the third month at two following visits. Thus, a relatively large proportion of patients underwent switching despite only moderate worsening of symptoms.
We found that disease activity, measured by the BAS-DAI, decreased significantly in both non-switchers and switchers under the treatment of first-line TNFis, but among switchers, this improvement was somehow less. On one hand, the primary lack of efficacy and early switching due to loss of efficacy (i.e. before the end of 1 year followup) may cause this difference, but on the other hand, the milder effect of the first-line drug before switching can also influence this result. As in our study, only 5 out of 77 switchers were primary non-responders to TNFi, we can suppose that the decrease of the BASDAI may be in connection with the risk of subsequent switching.
In our cohort, the age of the switchers was significantly higher than those of non-switchers at the start of the first TNFi. No differences could be demonstrated in the initial BASDAI values and disease duration. Switchers were more frequently women than men, but this difference was not statistically significant. This finding seems to be logical, as the TNFis are able to decrease inflammation, which is typical in earlier stages of the disease and presumably in younger age, but this difference was not reflected by the disease duration. In national registries, the higher median values of the initial BASDAI were congruent, but a higher percentage of women, shorter disease and symptom duration, and higher disease activity and functional indices were found among switchers compared to non-switchers [14, 15] .
Although the national registries and observational studies included relatively large numbers of patients undergoing TNFi switching, no data are available about the outcome of treatment with each TNFi, which is in agreement with the survival rate of these drugs. It is obvious that our study is underpowered due to the limited number of switches and the non-randomised study design, but noticeable results were obtained with respect to the reasons for stopping of each biological agent. In general, IE was the most common cause of the switching of primary treatment, which usually occurred at least 3 months after the start of treatment, so it was a secondary loss of effect. However, in the infliximab group, the ratio of side effects that led to switching was higher than in the other three groups. Most of these side effects were mild or moderate infusion reactions, which were sometimes outweighed and resulted in earlier switches than would have been necessary. But these side effects, and of course the secondary loss of efficacy, can be explained by the unique chemical structure of this drug [25] . The chimeric monoclonal antibody induces the production of anti-drug antibodies more intensively than the humanised ones (adalimumab and golimumab) and the receptor fusion protein etanercept. It was published recently that, in patients with spondyloarthropathies, anti-drug antibodies could be detected in 25.9 % of patients, most frequently in infliximab-treated patients (81.8 %) compared to those treated with adalimumab (18.2 %) and etanercept (0 %) [26] . As these anti-drug antibodies are responsible for treatment failures at least in some of the cases, it may support the validity of our results. Moreover, in our study, a sharp decrease was observed in the retention of infliximab treatment between the 13th and 17th months of treatment. These results agree with the above-mentioned study which could detect the appearance of anti-drug antibodies mainly at the end of the first year of the treatment (12.89 ± 5.92 months). In a meta-analysis that evaluated the presence and effects of anti-drug antibodies in patients with different inflammatory diseases, such as rheumatoid arthritis, spondyloarthropathies and inflammatory bowel diseases, the drug response was reduced if anti-drug antibodies could be detected in the sera of patients. Among different diseases, the effect of anti-drug antibody positivity on TNFi responses was more pronounced in AS and spondyloarthropathies than in other diseases [27] . As concomitant treatment with methotrexate or other immunosuppressive drugs reduces the production of these antibodies, and because in axial form of spondyloarthropathies these type of drugs are usually not administered, it may highlight the necessity of the determination of anti-drug antibodies in cases of loss of efficacy in AS, which may give further support for the decision of switching.
Among switchers, the effect of firstly and secondly used TNFis on disease activity measured by the BASDAI and the response rates measured by the BASDAI50 were similar during the 1-year follow-up period in our retrospective analysis. Although the rate of patients achieving BAS-DAI50 was somewhat higher than the values published recently by other investigators [14, 15] , our findings are comparable with those results. However, the drug survival times of TNFis used as second-line treatment were worse than in first-line treatment. These data suggest that switching to another TNFi may be a useful option and, in general, the response is not worse; however, the risk of switching is higher over time.
Limitations of this study include the retrospective, single-centre design, lack of unequivocal definitions for switching and short follow-up to detect the patients' responses to the treatment. However, we investigated a reasonably large population of patients treated in a real-life setting, which allowed us to analyse the efficacy, side effects and survival of each TNFis among patients with AS. In conclusion, our data indicate that switching between TNFis is a good therapeutic option if the patient failed to respond or is intolerant to the formerly used agent, but the humanised monoclonal antibodies or receptor fusion protein should be preferred.
